Abeona Therapeutics Inc. (ABEO) stock analysis

Healthcare · Biotechnology

From the 10-K filed 2026-03-17

Business type: Asset play

How it makes money

It earns by selling a single-application gene therapy to hospitals for rare skin disease, with revenue driven by patient treatment volume.

It derives product revenue from ZEVASKYN, a treatment for Recessive Dystrophic Epidermolysis Bullosa (RDEB). Patients require specialized medical centers to administer this autologous gene therapy. Consequently, earnings are fundamentally tied to the company's ability to activate qualified treatment centers and achieve recurring patient applications at these sites.

What protects it: the moat

It claims protection through regulatory designations and proprietary manufacturing processes, though these are management's stated assertions.

The company relies on FDA designations such as Orphan Drug status and Rare Pediatric Disease status to provide potential market exclusivity. Additionally, it asserts that its internal, commercial-scale manufacturing platform in Cleveland offers competitive advantages in reliability, scale, and process control for its specialized cell therapies.

What growth costs

It must heavily reinvest in research, clinical development, and specialized manufacturing infrastructure to sustain its pipeline and commercial operations.

The company incurs high operating expenses related to its internal cGMP manufacturing facility and ongoing R&D for its AAV-based gene therapy candidates. Because it is a commercial-stage company with limited experience, it must maintain these costly capabilities to satisfy stringent regulatory requirements and support the expansion of its treatment center network.

What could damage it

Failure to secure reimbursement for its high-cost therapies would permanently impair its ability to generate revenue from the treatment of rare diseases.

The commercial model depends entirely on the willingness of insurers or government programs to cover the substantial costs of ZEVASKYN. If reimbursement is unavailable or restricted, the company cannot profitably reach its target patient population, regardless of clinical efficacy.

About Abeona Therapeutics Inc.

Abeona Therapeutics Inc., a commercial-stage biopharmaceutical company, develops gene and cell therapies for life-threatening diseases in the United States. It develops ZEVASKYN, an autologous, cell-based gene therapy for the treatment of patients with recessive dystrophic epidermolysis bullosa. The company also develops ABO-503 to treat X-linked retinoschisis; ABO-504 for the treatment of stargardt disease; and ABO-505 to treat autosomal dominant optic atrophy. In addition, it is developing AAV-based gene therapy through its AIM vector platform programs. The company was formerly known as PlasmaTech Biopharmaceuticals, Inc. and changed its name to Abeona Therapeutics Inc. in June 2015. Abeona Therapeutics Inc. was founded in 1974 and is headquartered in Cleveland, Ohio.

Other companies in Biotechnology